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Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the 
Philadelphia chromosome (translocation between chromosomes 9 and 22), resulting in the formation 
of the hybrid BCR-ABL protein. Currently, the treatment of CML patients is performed with imatinib 
mesylate (IM), which promotes the elimination of leukemic cells by inhibiting the kinase activity of 
BCR-ABL. This study evaluated the effectiveness of IM by monitoring 22 CML patients in a chronic 
phase treated at the CEPON/SC with IM for a minimum follow-up period of two years. Cytogenetic 
Response (CR) and bone marrow biopsies (BMB) were evaluated before and after IM treatment. BMB 
were evaluated by detection of reticulin degree and vascularization. The results were correlated to the 
CR. Mean time to achieve CR was 9 months and was attained by 77.27% of the patients. The results 
from the initial BMB analysis showed that 59.09% presented reticulin of between 2+ and 4+ whereas 
after treatment, only 27.17% presented this degree. With regard to vascularization of the initial sample, 
90.91% were graded between II and IV, whereas after treatment, 40.91% had this degree. The results 
suggest a positive correlation of degree of reticulin and vascularization with CR.
Uniterms: Chronic myeloid leukemia/treatment. Imatinib mesylate/effectiveness/leukemia treatment. 
Bone marrow/biopsies. Fibrosis. Vascularization.
A Leucemia Mielóide Crônica (LMC) é uma doença mieloproliferativa caracterizada pela presença do 
cromossomo Filadélfia (translocação entre os cromossomos 9 e 22), que resulta na formação da proteína 
híbrida BCR-ABL. Atualmente o tratamento de pacientes com LMC é realizado com mesilato de 
imatinibe (MI), o qual promove a eliminação das células leucêmicas pela inibição da atividade quinase 
de BCR-ABL. O presente estudo avaliou a eficácia do MI por meio do acompanhamento de pacientes 
portadores de LMC em fase crônica, atendidos no CEPON/SC tratados com MI pelo tempo mínimo de 
dois anos. Foram avaliadas a Resposta Citogenética (RC) e as biópsias de medula óssea (BMO) antes 
e após o tratamento com MI. As BMO foram avaliadas quanto ao grau de reticulina e vascularização. 
Os resultados correlacionaram-se com a RC cujo tempo médio para obtenção da RC foi de 9 meses, 
sendo atingida por 77.27% dos pacientes. Na primeira BMO, 59.09% dos pacientes apresentaram grau 
de reticulina entre 2+ e 4+ e após o tratamento, apenas 27.17% apresentaram esta graduação. Quanto à 
vascularização da primeira amostra, 90.91% foram graduadas entre II e IV e após o tratamento, 40.91% 
apresentaram esta graduação. Os resultados sugerem uma correlação diretamente proporcional entre os 
graus de reticulina e vascularização com a RC.
Unitermos: Leucemia mielóide crônica/tratamento. Mesilato de imatinibe/eficácia/tratamento da 
leucemia. Medula óssea/biópsia. Fibrose. Vascularização.
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INTRODUCTION
Chronic Myeloid Leukemia (CML) is a clonal dise-
ase characterized by the presence of the Philadelphia (Ph1) 
chromosome, which results from a reciprocal and balanced 
translocation between chromosomes 9 and 22 (Sawyers, 
1999). The molecular consequence of this translocation is 
the generation of a hybrid protein called BCR-ABL, which 
presents increased tyrosine kinase activity, compromising 
the regulation of the cell cycle (Faderl et al., 1999; Sattler, 
Griffin, 2003). The diagnostic presumptive of CML usu-
ally arises with the results obtained in blood cell counts. 
The total leukocyte count is elevated and is invariably 
greater than 25,000/µL. The total leukocyte count rises 
progressively in untreated patients. Granulocytes at all 
stages of development are present in the blood and are 
generally morphologically normal. Blast cell prevalence 
is approximately 3% but can range from 0% to 10%. The 
platelet count is elevated in approximately 50% of pa-
tients and largely normal in the rest. Definitive diagnosis 
is obtained by evaluation of bone marrow biopsy (BMB), 
myelogram and cytogenetic examination (Lichtman et al., 
2006; Brasil, Ministério da Saúde, 2001; Geary, 2000).
The hematopoietic microenvironment of bone mar-
row (BM) is also changed in CML. This microenvironment 
is composed of stromal cells, accessory cells and their pro-
ducts (extracellular matrix proteins and cytokines), which 
influence the self-renewal, proliferation and differentiation 
of hematopoietic stem and progenitor cells (Vituri et al., 
2000; Vituri et al., 2006). Collagen type III, visualized 
by silver staining, is generally increased at diagnosis 
(reticulin fibrosis). In almost half of patients, the reticulin 
is remarkably increased in BM, and this increase shows a 
correlation with the proportion of megakaryocytes (Licht-
man et al., 2006; Guimarães et al., 2006). The BM of CML 
patients have a two-fold increase in microvessel density 
compared to healthy controls while in CML there is more 
angiogenesis in BM than is found in other forms of leuke-
mia. The concentration of vessels, or the BM microvessel 
density (MVD), can easily be investigated by immunohis-
tochemistry in hematological disorders because the BM 
is a primary site of disease activity and readily accessible 
tissue. This measurement is also useful for evaluating the 
prognosis of patients (Panteli et al., 2004).
Regarding treatment of CML, imatinib mesylate 
(IM) is currently the first-line drug of choice. This drug, 
chemically known as 2-phenylaminopyrimidine, entered 
clinical trials in 1998 as STI571. The drug is a potent and 
specific inhibitor of all ABL related kinases, Platelet Deri-
ved Growth Factor (PDGF) and c-kit. As the hybrid protein 
BCR-ABL is responsible for the occurrence of events 
related to the LMC, its inhibition leads to the elimination 
of leukemic cells (Savage, Antman, 2002).
This study examined the BM stromal of CML 
patients treated with IM correlating to other laboratory 
parameters. The effectiveness of the drug was analyzed 
over a two-year period of monitoring based on observa-
tion of the time needed for patients to achieve CR. The 
BMB were evaluated for degree of reticulin (fibrosis) and 
degree of vascularization. Finally, the results obtained 
from the analysis of BMB collected after treatment, were 
correlated to CR.
PATIENTS AND METHODS
Firstly, a survey was carried out involving all regis-
tered patients with CML treated using IM at the Oncology 
Research Center Units of Santa Catarina, in Florianópo-
lis, Santa Catarina (CEPON/SC) in the period spanning 
from August 2005 to August 2007. During the period, 67 
patients were enrolled, all from Santa Catarina. Only the 
22 patients that presented at least two reports of anatomi-
cal and pathological bone marrow, one of diagnosis and 
another after 6±2 months of treatment with IM, were con-
sidered for the study. Therapy with IM, at a daily dosage 
of 400 mg was given throughout the study, and no other 
cytotoxic or supportive agents were combined to IM. 
Inclusion criteria
Patients with CML at a chronic phase, Ph1 chromoso-
me positive, treated with IM, submitted to two BMB, and 
able to perform histological sections, were included. The 
determination of the stage of disease was done according 
to the laboratory peripheral blood findings (Table I) and 
findings on BMB (Table 2) (Sawyers, 1999). All patients 
included were previously treated with IFN-a before star-
ting the use of IM. Patients were informed in accordance 
with the guidelines of the local ethics committee (CONEP/
ANVS). The demographics and baseline characteristics of 
the patients included in the study are shown in Table III.
TABLE I - Laboratory findings of peripheral blood of CML 
patients, at a chronic phase
 
Peripheral Blood 
Leukocytosis (> 25,000/mm3)
Platelets: Increased or normal
Basophilia
Reduced activity of leukocyte alkaline phosphatase 
All stages of granulocyte differentiation visible in peripheral 
blood smears
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Cytogenetic response
The analysis of Cytogenetic Response (CR) was 
done by examining the medical records of patients. CR 
was acknowledged when patients achieved Major Cytoge-
netic Response, according to current treatment guidelines 
for CML in Brazil (Table IV). The tests were evaluated in-
dividually and were used to analyze a possible correlation 
between CR and degrees of reticulin and vascularization. 
The data used to construct the graph considered the per-
centage of chromosome Ph1 positive cells and the grading 
of the second BMB, related to the degree of reticulin and 
vascularization (Figures 6 and 7).
Gomori staining
BMB slides were prepared from paraffin-embedded 
blocks. After deparaffinization, the BMB slides were 
immersed in potassium permanganate solution 0.5% 
(Quimex) for 2 minutes. The slides were then washed 
and immersed quickly in oxalic acid solution 5% (Ve-
tec). Subsequently, these were immersed in alumen iron 
solution 5% (Reagen) for 2 minutes. After washing, the 
slides were immersed in silver ammonium solution - 
Gomori (Vetec) for 2 minutes. After immersion in distil-
led water, the slides were quickly immersed in formalin 
TABLE II - Findings on BMB of CML patients, at a chronic phase
 
Bone Marrow
Hypercellularity
Reduction of intramedullary fat 
Increased number of megakaryocytes
Less than 10% of blasts and promyelocytes
Increased myeloid to erythroid cell ratio
TABLE III - Patient demographics and baseline characteristics
Patient demographics and baseline characteristics Values
Nº patients 22
Male Sex, % 50
Median Age (range) 42.36 (18 to 69y)
History of illness, usage of INF-a, number of patients (%)
Hematologic/cytogenetic resistance 12 (54.54)
Intolerance 7 (31.82)
No reason 3 (13.64)
INF-a therapy duration, number of patients (%)
> 1 year 15 (68.18)
< 1 year 7 (31.82)
Splenomegaly, number of patients (%) 10 (45.46)
Time diagnosed with disease (early treatment with imatinib), number of patients (%)
< 1 year 0 (0)
> 1 year 22 (100)
Hemoglobin level at diagnosis, number of patients (%)
< 12.0 g/dl 14 (63.64)
> 12.0 g/dl 8 (36.36)
Leukocytes count at diagnosis, number of patients (%)
< 10,000/mm3 0 (0)
10,000-50,000/ mm3 15 (68.18)
> 50,000/ mm3 7 (31.82)
Platelet count at diagnosis, number of patients (%)
< 450,000/ mm3 13 (59.09)
> 450,000/ mm3 9 (40.91)
Peripheral blasts at 1st evaluation, number of patients (%) 14 (63.64)
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solution 10% (Vetec) and washed under running water. 
Subsequently, the slides were immersed in chloride old 
solution 1% (Synth) and in sodium thiosulfate solution 
5% (Vetec). Finally, the sections were coverslipped with 
a specific fixation fluid (Entellan, Merck) (Michalany J, 
1980).
- Measurement of fibrosis degree (reticulin fiber 
network)
The histological sections of BMB were examined 
using a light microscope. The entire section was scanned 
at 100 x magnification. Positive and negative control sam-
ples were evaluated concomitantly. The positive controls 
were from patients with Primary Myelofibrosis (Chronic 
Idiopathic Myelofibrosis) and the negative controls were 
from patients without hematological disease. The reticulin 
fibers were graded as 0 to 4+. The classification used was 
based on the Bauermeister Graduation (Alves, 2009). The 
normal samples had a degree of reticulin 0, indicating ab-
sence of reticulin, and served as negative controls (Figure 
1A). Samples with the presence of thin and scattered fibers 
or a focal network had degree 1+, also normal. The visuali-
zation of a thin fiber network in most of the fragment, and 
absence of thick fibers, represent degree 2+. Samples with 
a diffuse network of thin fibers with scattered thick fibers 
and absence of collagen were graded 3+. Samples with a 
diffuse network of coarse fibers and bundles of collagen 
were graded as 4+, similar to the positive controls (Figure 
1B) (Alves, 2009; Bueso-Ramos et al., 2004).
Immunohistochemistry for CD34
Bone marrow microvessels were visualized by an 
immunohistochemical labelled for CD34. Although the 
CD34 antibody also stained myeloid progenitors, the 
number of cells stained was sufficiently small as not to 
interfere with our analysis. Nevertheless, vessel specificity 
the CD34-stained stroma considered for analysis was do-
cumented thoroughly. In general, CD34 has been found to 
be a useful antigen for assessing intratumor angiogenesis 
(Kvasnicka et al, 2004).
Slides of the BMB were prepared from paraffin-em-
bedded blocks. After deparaffinization, slides were steam 
pretreated in a solution containing 200 mL of methanol 
and 4 mL of hydrogen peroxide (Merck, concentration 
30%) for 20 minutes, protected from the light. After wa-
shing with buffer at pH 7.2, the slides were immersed in a 
citrate buffer, with pH 6.0 called Target Retrieval (Dako), 
for exposure to the antigen, for 45 minutes in a water bath 
at 85 °C. After cooling the solution for approximately 20 
minutes, the slides were washed in buffer solution. Before 
incubating the slides, the tissue sections were demarcated 
with a hydrophobic pen. The primary antibody (CD34, 
TABLE IV - Criteria for classification of CR (Brasil. Ministério 
da Saúde, 2001)
Cytogenetic Response
Major Cytogenetic Response:
 - Complete Cytogenetic Response: 0% Ph1 positive cells
 - Partial Cytogenetic Response: 1% to < 35% Ph1 positive cells
Minor Cytogenetic Response: 35% to 90% Ph1 positive cells
Lack of Cytogenetic Response: > 90% Ph1 positive cells
FIGURE 1A - Histological sections of normal BMB (degree 
0) stained by Gomori silver solution, 100 x magnification. The 
fibers are stained in gray. 
FIGURE 1B - Histological section of BMB stained by Gomori 
silver solution, 100 x magnification. The fibers are stained in 
gray. This sample presents reticulin network graded as +4.
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Novocastra) was then incubated overnight in a 1:100 
dilution at room temperature. The biotin-streptavidin kit 
(Novocastra) was used for antigen visualization and was 
incubated for 30 minutes at room temperature. Finally, 
Diaminobenzidine (DAB, Dako) was used as the substrate 
for the abovementioned marker enzyme. The sections were 
counterstained with hematoxylin (Merk) and coverslips 
were applied with a specific fixation fluid (Entellan, Merk) 
(Dabbs, 2006).
- Measurement of microvessel density
The BMB histological sections, stained immuno-
histochemically for CD34, were examined using a light 
microscope in order to identify the areas with intense 
vascularization. The entire section was scanned at 100 x 
magnification. Three areas, with the highest number of 
microvessels, were chosen and defined as the hot spots. 
Microvessels were then counted at 400 x magnification in 
each of these hot spots.
The final MVD number was assigned by taking 
the average of the three separate visual counts. Micro-
vessels were identified as endothelial cells, either single 
or clustered in nets or tubes, clearly separated from one 
another, either with or without a lumen (Figure 2A). 
Vessels with muscular walls and vessels in the perios-
teum and open sinusoids were excluded. Measurement 
also excluded areas occupied by fat. The vascularization 
was graded from I to IV degrees (Kvasnicka, 2004). 
Positive and negative control samples were evaluated 
concomitantly. The positive controls were obtained from 
patients with Multiple Myeloma whereas the negative 
controls were from patients without hematological disease 
(Figure 2B).
Data and statistical analysis
The percentage of patients that achieved CR in the 
two years of treatment and the degree of reticulin and vas-
cularization of the BMB were evaluated. The first biopsy 
was performed before IM treatment and the second sample 
was collected after at least six months of IM treatment.
The tests of correlation were also performed be-
tween CR and the degree of vascularization and reticulin 
from the second BMB. The patients who responded were 
those with less than 35% of Ph1 chromosome positive cells 
on the cytogenetic examinations. The evaluation of this 
correlation was verified with the non-parametric test of 
Spearman, considering p< 0.05 as the minimum level of 
significance. Results were expressed in absolute values of 
correlation (r), where “0” indicates total absence of linear 
correlation and “1” a perfect linear relationship. Statistical 
analysis was performed using the INSTAT-2 program.
RESULTS
1- The study was conducted in 22 individuals tre-
ated with IM that met the inclusion criteria. During the 
two years of monitoring, 77.27% patients achieved CR 
(Figure 3). By the sixth month, nearly 22% of patients had 
achieved CR and at the tenth month, 50% had attained this 
response. The last patient attained CR just in the fourteenth 
month. Beyond this timepoint, no other patients achieved 
CR throughout the rest of the monitoring. The average 
time taken to attain CR was 10 months.
FIGURE 2A - Histological section of normal (degree I) BMB 
stained immunohistochemically for CD34, 100 x magnification. 
F IGURE 2B -  Histological  sect ion of  BMB stained 
immunohistochemically for CD34, 400 x magnification. 
Microvessels are stained in brown, clearly separated from one 
another, and either with or without a lumen. This sample was 
graded as degree IV vascularization.
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2- Regarding evaluation of reticulin degree of the 
first BMB, 59.09% of the samples showed significant fi-
brosis and were graded between 2+ and 3+ while 13.64% 
revealed myelofibrosis (degree +4). Only 9.09% of 
samples collected before treatment with IM were normal 
(degree 0) and 22.73% were graded as 1+. After treatment, 
less than half the samples were graded between 2+ and 
3+ (22.73%), while no reticulin fibers (degree 0) were 
visualized in 45.46% of the BMB, and only 4.54% were 
graded as 4+ (Figure 4).
3-For the degree of vascularization of the first BMB, 
77.27% revealed a significant increase in the number of 
vessels, and were graded between III and IV. Only 9.09% 
of the pre-treatment samples were considered as having 
normal vascularity (degree I) and a small number of sam-
ples (13.64%) were graded as II. 
After IM treatment, the number of samples with a 
degree of vascularization between III and IV was about 
4 times lower compared to the number obtained before 
treatment (18.18%) and 27.27% of samples were graded at 
II. Most samples (54.54%) were considered to have normal 
vascularity and were graded as I (Figure 5).
4- The evaluation of reticulin degree of the BMB 
collected after IM was correlated to CR (Table V). Among 
patients who had their BMB graded at 0 reticulin, 90% 
achieved CR. The patients who presented 1+, 2+ and 3+ 
reticulin in the second sample, 80%, 75% and 50% of 
these achieved CR, respectively. None of the patients with 
second BMB graded as 4+ reticulin achieved CR. These 
data are presented in Figure 6. The results of cytogenetic 
tests were assessed from each patient record, observing 
the percentage of chromosome Ph1 positive cells and the 
reticulin degree of the second BMB. Points below the line 
represent patients who achieved CR and points above the 
line represent patients who did not achieve CR. The value 
of “r” obtained by Spearman’s correlation test was 0.8082 
and the value of P was < 0.0001.
5- The results obtained from the assessment of de-
gree of vascularization of BMB collected after IM were 
correlated with CR (Table VI). No patients with BMB 
graded as IV achieved CR. Among patients with degrees I, 
II and III of vascularization, 91.67%, 83.33% and 33.33% 
achieved CR, respectively. These results show that the 
percentage of patients responding increases as the degree 
of vascularization decreases. In this situation, there is also 
an inverse correlation with CR. These data are also shown 
in graph form (Figure 7). For the construction of this graph, 
the results of cytogenetic tests from each patient were used, 
FIGURE 3 - Time required for patients to achieve CR. Patient 
monitoring was performed for 2 years. 
FIGURE 4 - BMB distribution of CML patients included in the 
study, according to Fibrosis/Reticulin degree (Gomori stain).
FIGURE 5 - BMB distribution of CML patients included in the 
study, according to vascularization degree.
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noting the percentage of chromosome Ph1 positive cells and 
vascularization degree of BMB collected after treatment. 
Points below the line represent patients who achieved CR 
and points above the line represent patients who did not 
achieve CR. The value of “r” obtained by Spearman’s cor-
relation test was 0.8179 and the value of P was < 0.0001.
DISCUSSION
The therapy used to treat CML patients was extremely 
limited up until the late 1970s. This changed when IFN-a 
came into use. The disadvantage of the use of IFN-a is that 
the reversal of myelofibrosis occurs only at high doses of the 
drug and the side effects of this medication are significant. 
Attaining CR is the main goal of treatment, since this is 
TABLE V - Relationship between Reticulin degree of BMB from CML patients collected after IM treatment and CR  
Reticulin degree of BMB (after 6 to 12 
months of IM treatment)
Distribution of BMB after IM by 
reticulin degree (%)
% of patients that achieved CR 
 0  45.46  90
 +1  27.27  80
 +2  13.64  75
 +3  9.09  50
 +4  4.54  0
FIGURE 6 - Distribution of patients according to reticulin 
degree on second BMB and percentage of Ph1 chromosome 
positive cells obtained in first cytogenetic examination 
performed after treatment with IM. Points below the line 
represent patients who achieved CR, while points above the line 
represent non- responders. This graph was constructed assuming 
a cytogenetic response occurs when there is less than 35% 
Ph1 chromosome positive cells on the cytogenetic test (Major 
Cytogenetic Response).
TABLE VI - Relationship between Vascularization degree of BMB from CML patients collected after IM treatment and CR
Vascularization degree of BMB (after 6 
to 12 months of IM treatment)
Distribution of BMB after IM by 
vascularization degree (%)
% of patients that achieved CR
 I  54.54  91.67
 II  27.27  83.33
 III  13.64  33.33
 IV  4.54  0
FIGURE 7 - Distribution of CML patients according to 
vascularization degree on second BMB and percentage of 
Ph1 chromosome positive cells obtained in first cytogenetic 
examination performed after treatment with IM. Points below 
the line represent patients who achieved CR, while points above 
the line represent non-responders. This graph was constructed 
assuming a satisfactory response occurs when there is less than 
35% Ph1 chromosome positive cells on the cytogenetic test.
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directly related to patient survival. In addition, individuals 
who do not respond are called refractory and this event is 
associated to disease progression and worse prognosis (Gui-
marães et al., 2006; Buesche et al., 2004; Sattler, Griffin, 
2003; Goldman, Mello, 2003; Druker, Talpaz, Resta, 2002).
The results obtained showed that 77.27% of patients 
presented less than 35% of chromosome Ph1positive cells 
in the cytogenetic tests during the monitoring period. The 
average time to achieve CR response was ten months. 
Although some patients proved to be refractory to IM, 
they continued the treatment for at least two years. The 
percentage of patients that achieved CR in this study 
exceeded the figure reported by another study in patients 
resistant to IFN-a, posteriorly treated with IM (Guilhot, 
2004). The cited study, which has been used as a compa-
rison, considered the stage of disease, and 60% of patients 
who were at a chronic phase achieved CR. In contrast, 
the CR attainment rates among patients who were at an 
accelerated phase and blast crisis were only 24% and 16%, 
respectively. The results of this study and those of other 
researchers have shown that patients who failed to attain 
CR within 2 years of treatment are probably refractory and 
present poor prognosis (Guilhot, 2004).
The evaluation of fibrosis by reticulin analysis was 
investigated because the BMB of CML patients generally 
exhibit a significant increase in reticulin fibers (Zago, 
Falcão, Pasquini, 2001). Moreover, myelofibrosis is asso-
ciated historically with poor CML prognosis. The platelet-
derived growth factor (PDGF) is a cytokine involved in 
myelofibrosis development in CML patients treated with 
IM (Kantarjian et al., 2005). Expression of this growth 
factor stimulates fibroblast activities including prolife-
ration, migration and deposition of various extracellular 
matrix proteins, such as collagens, fibronectin, laminin 
and others (Anjos, Alvarez-Silva, Borelli, 2004). Some 
studies have shown that IM also acts on the BM stroma 
(Bueso-Ramos et al., 2004; Klion, 2004) .The drug acts not 
only by blocking the ATP link to the binding site of protein 
tyrosine kinase BCR-ABL but also acts by blocking the 
bind site of PDGF, present in fibroblasts. These cells are 
involved in the release of various elements that compose 
the extracellular matrix of BM, such as reticulin. IM has 
an independent anti-fibrotic effect on BM of CML patients, 
while IFN-a proves ineffective in patients with myelofi-
brosis at diagnosis (Kantarjianet al., 2005; Buescheet al., 
2004; ; Mello, 2004;; Klion et al., 2004; Suetterlin et al., 
2004; Hasselbach et al., 2003).
Regarding the reticulin analysis of BMB, 18.18% 
of samples collected before IM treatment presented a thin 
fiber network in most fragments (degree 2+), 36.36% sho-
wed a diffuse network of thin fibers with scattered thick 
fibers (degree 3+) and 13.64% of samples showed coarse 
fibers and bundles of collagen (degree 4+), giving a total of 
68.18% with significant changes in the reticulinic network. 
In contrast, 45.46% of BMB collected after the therapy 
revealed absence of reticulin (degree 0) and 27.27% sho-
wed thin and scattered fibers or a focal network (degree 
1+), 13.64% of samples were graded as 2+ and 9.09% as 
3+. Interestingly, no samples revealed the highest degree 
of reticulin (4+). These results strengthen the hypothesis 
that the drug acts on the BM stroma and has the ability to 
reverse fibrosis. Several reports have shown significant 
reductions in myelofibrosis in patients with CML receiving 
IM. Bueso-Ramos et al. (2004) reported resolution of at 
least 2 degrees in 19 of their 31 patients (61%) and by at 
least 1 degree in 34 patients (85%). However, no correla-
tion with cytogenetic response was found. Buesche et al 
(2007) also showed resolution of fibrosis, although during 
a follow-up period of up to 4.8 years, small foci with ab-
normal fiber increase emerged. In our study, patients were 
followed for only two years. In addition, IM is also being 
tested as a potent antifibrotic therapeutic agent in several 
diseases and beneficial results have been found that may 
not only halt further progression but also induce regression 
of preexisting dermal fibrosis (Akhmetshina et al., 2009). 
As in CML, there is a change in the distribution of 
elements present in the extracellular matrix of BM, and it 
has been suggested that the leukemic cells are protected 
or “hidden” by these elements. The increased fibrosis 
could hinder the performance of the drug, not allowing the 
apoptosis of Ph1 chromosome positive cells (Klion et al., 
2004). The study suggested that in samples where there 
was a reduction of fibrosis, the drug worked more easily 
on the leukemic cells.
As the IM acts on the stroma of BM, there is the possi-
bility that the reduction of fibrosis provides better conditions 
for the performance of the drug, which explains the analysis 
of correlation between CR and reticulin degree. The present 
results showed that there is a significant correlation between 
CR and degree of reticulin. Among the patients with degree 
0 of reticulin on the second BMB, 90% had achieved CR. 
Of those who had degree 1+ and 2+ of reticulin, 80% and 
75% achieved CR, respectively. Finally, a total of 50% and 
0% of patients who had their samples graded as 3+ and 4+ 
responded, respectively. However, Kantarjian et al. (2005), 
in a study of 110 patients with CML who had severe fibrosis 
(61%) and mild-moderate fibrosis, found no association 
between severe marrow fibrosis and poor response to IM 
or worse prognosis. These results do not corroborate with 
findings of our study. This is probably because the patients 
were older (range 24-81 years) and the association was 
performed with the first biopsy, since the prevalence of 
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myelofibrosis increases with age. In addition, our analysis 
included only 22 patients.
An increase in angiogenesis has been observed in pa-
tients with hematological diseases, including CML (Lun-
dberget al. 2000). One study investigated the role of IM 
on the BM angiogenesis in comparison with Hydroxyurea 
and IFN-a. The paper reported that, in vitro, the expression 
of Vascular Endothelial Growth Factor (VEGF) reduced 
after treatment with IM. Also, the study suggested that the 
decrease in microvascularization presents an association 
with the reversal of myelofibrosis (Kvasnicka et al., 2004). 
The methods used in the present study to assess the vascu-
larity of BM followed were the same as those adopted in 
the aforementioned study, which employed the technique 
of immunohistochemical expression of CD34 present in 
endothelial cells. Akin to fibrosis, vascularization is also 
altered in CML. Therefore, it has been suggested that the 
number of vessels also have an important role in disease 
progression and therapeutic response (Kvasnickaet al., 
2004). And as a consequence, there may be a correlation 
with the prognosis of patients. Bone marrow study of 
angiogenesis was performed by using microvessel visual 
grading with antibody CD 34. The analysis showed that, 
of the first samples collected prior to treatment with IM, 
degree IV occurred in 36.36% patients, degree III in 
40.91%, degree II in 13.64%, and degree I in only 9.09%. 
However, in the analysis of vessels on the second biopsy 
after IM treatment, few patients showed degree III, degree 
II was evident in 27.27% and more than half the samples 
(54.54%) presented degree I. The results of our study 
corroborate those reported in the literature, showing that 
blood vessel density of patients decreased after 3 months 
on IM (Rumpel, Friedrich, Deininger, 2003). 
Since some researchers have shown that IM acts 
on BM vascularization, we also performed correlation 
analysis of this parameter with CR. Our results showed 
a high correlation between the vascularization of BM 
samples collected after treatment and CR. Among the 
patients with degree I and II of vascularization on the se-
cond BMB, 91.67% and 83.33% attained CR, respectively. 
Among patients whose samples were graded as III, 33.33% 
responded, while none of the patients with degree IV of 
vascularization achieved CR. 
The present study strengthens the hypothesis that the 
stroma of patients with CML presents significant changes, 
and that IM is effective in normalizing this microenviron-
ment, demonstrating correlation between stabilization 
and CR. In addition, in samples where the stroma is more 
disorganized, the drug appears to have greater difficulty 
acting. Consequently, the BM status of patients with CML 
has a direct correlation with prognosis.
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